Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
(b) Resignation of Principal Accounting Officer
Effective as of December 31, 2020, Yi Ching Yau, the Company's current Chief
Accounting Officer, resigned from her role as principal accounting officer.
Ms. Yau will continue in her role as Chief Accounting Officer.
(c) Designation of Principal Accounting Officer
Effective January 1, 2021, the Board of Directors of BridgeBio Pharma, Inc. (the
"Company") designated Brian C. Stephenson, Ph.D., CFA, the Company's
current Chief Financial Officer and principal financial officer, as its
principal accounting officer, as such term is used for purposes of the rules and
regulations of the Securities and Exchange Commission. Dr. Stephenson, age 40,
will oversee the Company's accounting matters.
Dr. Stephenson has served in his current role as the Company's Chief Financial
Officer and principal financial officer since October 2018. Prior to joining the
Company, Dr. Stephenson served as Partner and the Head of Life Sciences for
Capital IP Investment Partners, a special situation investment fund, from 2015
to 2018. From 2011 to 2014, Dr. Stephenson was a Director/Vice President Leerink
Partners, an investment bank. Prior to that, Dr. Stephenson was an Engagement
Manager at McKinsey & Company, a worldwide management consulting firm. He
received his Ph.D. and M.S. degrees in chemical engineering from the
Massachusetts Institute of Technology and his B.S. in chemical engineering from
Brigham Young University. Dr. Stephenson is also a Chartered Financial Analyst
charterholder.
Dr. Stephenson is party to an Offer Letter, dated October 28, 2018, with
BridgeBio Services, Inc., a copy of which is filed as Exhibit 10.20 to our
Registration Statement on Form S-1 (333-231759) filed on June 11, 2019 and
incorporated herein by reference. Dr. Stephenson is not receiving any additional
compensation in connection with his designation as principal accounting officer.
There are no arrangements or understandings between Dr. Stephenson and any other
persons pursuant to which Dr. Stephenson was appointed as principal accounting
officer of the Company. There are also no family relationships between
Dr. Stephenson and any director or executive officer of the Company and he has
no direct or indirect interest in any transaction or proposed transaction
required to be disclosed pursuant to Item 404(a) of Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses